Dose Ranging Study of Albiglutide in Japanese Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 215 participants.
Also called NCT01098461
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 215 participants
- Sponsor
- Registry
-
NCT01098461
-
- Other papers using this trial's data
- A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01098461. Randomized; double masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2014-07-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose Ranging Study of Albiglutide in Japanese Subjects
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Biological)
- albiglutide
- Intervention (Biological)
- placebo
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01098461- Content hash
8cd4f6895f6927d297d3f95457ee9686a1ef9b6c9af453286ecdde6863c3c86b